Concurrent acalabrutinib, bendamustine, and rituximab in the first-line setting improved outcomes for patients with mantle cell lymphoma (MCL) relative to sequential treatment without acalabrutinib.

In chronic myeloid leukemia, combining asciminib with a tyrosine kinase inhibitor shows increasing efficacy and tolerability over 3 years.

Removing etoposide did not negatively affect OS, DFS, MRD, or relapse rate at 3 years for pediatric patients with LR1, LR2 or high-risk AML.

Epcoritamb plus lenalidomide and rituximab improves PFS and complete response in patients with relapsed/refractory follicular lymphoma in second line compared with lenalidomide and rituximab alone.

A treatment strategy of targeted therapy first allowed more than half of patients with newly diagnosed DLBCL to achieve a CR without chemotherapy.

Many families with children being treated for acute lymphoblastic leukemia face household material hardship and/or income loss.

Targeted immunotherapy significantly improved responses and prolonged survival in newly-diagnosed Ph+ ALL compared with chemotherapy.

In patients with follicular lymphoma being treated in the third-line setting or later, liso-cel therapy is associated with durable responses.

KRd significantly prolonged progression-free survival and improved the MRD negativity rate compared to VRd in newly diagnosed multiple myeloma.

Investigators analyzed IBD subtypes and their associated risks of radical prostatectomy complications among a cohort of patients with prostate cancer to fill a knowledge gap.

A review of EMR data from younger and older women with breast cancer noted that social support was not consistently documented among patients.

Treatment with rituximab plus epcoritamab has achieved rapid and deep responses in follicular lymphoma patients with a high tumor burden.